A pill after sex that can prevent both syphilis and chlamydia? DoxyPEP promises fewer infections, but experts address one big risk
Sexual health has been moving towards greater prevention in recent years. Alongside familiar strategies such as PrEP for HIV, a new approach - doxyPEP - is coming to the fore. The term, which is gradually emerging outside professional circles, refers to the use of an antibiotic after sex to prevent certain sexually transmitted infections. And early data suggest that this may be a significant shift.
What is doxyPEP and how does it work
DoxyPEP (from the English doxycycline post-exposure prophylaxis) means taking the antibiotic doxycycline shortly after sexual contact. The principle is relatively simple - if a person takes a single dose - usually 200 mg - ideally within 24 hours after sex (at the latest within 72 hours), this can prevent the development of a bacterial infection.
This is not a new drug. Doxycycline has been used for decades, for example to treat acne, Lyme disease or malaria. What is new is its use in the prevention of sexually transmitted infections, especially syphilis and chlamydia.
Data that have attracted attention
A major impetus for research into this drug came from a University of Washington study published in the peer-reviewed journal Clinical Infectious Diseases. It looked at the impact of the introduction of doxyPEP in King County (Washington State) - and the results are striking.
According to the researchers, more than 3,000 cases of syphilis have been prevented through this strategy, representing an approximate 52% reduction in incidence. This is one of the most convincing pieces of evidence that, when used more widely, doxyPEP can significantly impact the epidemiology of certain infections.
Why doxyPEP is mainly talked about in the queer community
DoxyPEP has spread fastest among gay men, bisexual men, and trans women. The reason is partly practical. Namely, these groups have long been among the hardest hit by certain bacterial STDs, including syphilis.
At the same time, experience with other forms of prevention also plays a role. Communities that have been through decades of HIV prevention are used to working with the concept of 'treatment as protection'. Both PrEP and PEP, the medications used to prevent HIV disease, have changed perceptions of sexual health, and doxyPEP builds on this approach.
What doxyPEP addresses - and what it doesn't yet
Although the results are optimistic, it is not a one-size-fits-all solution. DoxyPEP is primarily effective against bacterial infections such as syphilis and chlamydia. Conversely, it does not protect against HIV or viral infections such as herpes.
It is also not routinely recommended for all groups. For example, its use is restricted in pregnant women because of possible risks to the foetus. This means that some parts of the population remain outside its main benefit.
The biggest question mark: antibiotic resistance
However, any wider use of antibiotics raises the issue of resistance. Experts warn that if doxycycline is used prophylactically on a large scale, it could affect bacteria in the body and potentially contribute to making some infections harder to treat in the future.
Research to date suggests that the bacteria that cause syphilis and chlamydia develop resistance to doxycycline more slowly than other pathogens. Nevertheless, this is an area that scientists continue to monitor closely.
At the same time, the wider impact on the microbiome or other bacteria in the body is also being discussed. So the benefits are clear, but the long-term implications have not yet been fully explored.
Prevention as the new standard?
DoxyPEP fits into a broader change in approach to sexual health. Instead of reacting to disease, there is an increasing emphasis on prevention - trying to prevent infections before they develop.
It is not a substitute for other measures. Experts point out that it should be part of a comprehensive approach that includes regular testing, awareness and open communication with health professionals.
DoxyPEP is therefore not a 'magic pill', but rather another tool that, if used correctly, can significantly reduce the risk of certain infections. And it also opens up the debate about what sexual health prevention will look like in the years to come.
